Key Takeaways
- • OrbiMed Advisors has secured about $3 billion across two new healthcare venture funds, according to the Wall Street Journal.
- • OrbiMed Private Investments X raised more than $1.9 billion, its 10th U.S. and European venture fund and the firm's largest for venture investments in those territories.
- • OrbiMed Asia Partners VI raised more than $1 billion, its sixth Asia pool and also the firm's largest venture vehicle in the region.
- • The closes come despite a slide in healthcare venture capital fundraising this year, and follow several portfolio companies that recently went public or were acquired.
Summary
New York-based OrbiMed Advisors has raised about $3 billion across two new healthcare venture funds, according to a Wall Street Journal exclusive report dated October 15, 2026. The raises are notable because they arrive during a slowdown in healthcare venture fundraising this year, according to the report.
The larger of the two vehicles, OrbiMed Private Investments X, collected more than $1.9 billion. It is the firm's 10th U.S. and European venture fund. The second, OrbiMed Asia Partners VI, raised more than $1 billion and is the sixth Asia pool from the firm. Both funds are the largest the firm has raised for venture investments in their respective territories.
The fundraising follows OrbiMed's track record of backing companies that have recently gone public or been acquired, which the Journal cites as a factor in the strong investor demand. The report does not disclose the specific limited partners in either fund or the target allocation strategies.
The larger of the two vehicles, OrbiMed Private Investments X, collected more than $1.9 billion. It is the firm's 10th U.S. and European venture fund. The second, OrbiMed Asia Partners VI, raised more than $1 billion and is the sixth Asia pool from the firm. Both funds are the largest the firm has raised for venture investments in their respective territories.
The fundraising follows OrbiMed's track record of backing companies that have recently gone public or been acquired, which the Journal cites as a factor in the strong investor demand. The report does not disclose the specific limited partners in either fund or the target allocation strategies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.